Portola Pharmaceuticals Lands $60,000,000 New Round

  • Feed Type
  • Date
    7/9/2008
  • Company Name
    Portola Pharmaceuticals
  • Mailing Address
    270 E. Grand Avenue South San Francisco, CA 94080
  • Company Description
    Portola Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development. The most advanced compound is an oral Factor Xa inhibitor that is entering a Phase II trial for the prevention of DVT in patients undergoing knee surgery.
  • Website
    http://www.portola.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds will be used primarily to advance Portola’s two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company’s pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants.
  • M&A Terms
  • Venture Investor
    D. E. Shaw Group
  • Venture Investor
    Adage Capital Management
  • Venture Investor
    BBT Fund
  • Venture Investor
    Pac-Link Bio Venture Investment Corporation

Trending on Xconomy